Chemours is trading 11% down at $15.95 after reporting second-quarter 2026 results that missed analyst estimates for both revenue and earnings per share.
- Management issued cautious Q3 guidance, forecasting adjusted EBITDA between $175M and $205M, which signals a sequential decline and has dampened investor sentiment.
- While adjusted EBITDA was supported by pricing gains and growth in Advanced Performance Materials, these factors were insufficient to offset the broader earnings miss.
- The stock's decline appears to be company-specific, as the broader materials sector is trending higher today.